Early degeneration of the Sorin Mitroflow aortic bioprosthesis
We report a series of 31 patients after surgical aortic valve implantation of a bovine Sorin Mitroflow bioprosthesis with early severe structural valve degeneration (SVD) despite absence of known risk factors. Half of the patients underwent re-intervention and more than one third died without re-intervention, mostly prematurely due to heart failure caused by SVD. The Sorin Mitroflow valve was prone to early SVD even in very old patients, which may be at least in part due its specific design with an externally mounted pericardial sheet and to a former lack of anti-calcification treatment. This led to additional suffering of the patients and added healthcare expense. The inferior durability of the advanced versions of the valve was largely undetected for almost two decades, which in retrospect was mainly because earlier studies relied on SVD diagnosis only at reoperation, lacked regular echocardiographic monitoring and did not consider the competing risk of death despite high mortality rates. To avoid a similar delay in the recognition of specific problems with new surgical valves the introduction of mandatory SAVR registries is suggested analogue to the already ongoing TAVI registries. Moreover, regular echocardiographic monitoring and uniform definition of SVD as well as broad training of all cardiologists and echocardiographers involved in SVD screening and treatment seem reasonable.
“The surgeon carries an important responsibility in protecting the patient from valve degeneration”
Flameng W, et al. (2014)
Severe aortic valve disease – predominantly degenerative aortic valve stenosis – is the most important valve disorder in the elderly with increasing numbers and burden during the past decades . The treatment of choice is valve replacement either as surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI). In surgical aortic valve replacement, the proportion of bioprosthetic aortic valves is continuously increasing in all age groups and is overall much higher than that of mechanical aortic valves [2–4]. For bioprostheses excellent longevity and performance is mandatory, so that the prosthesis, if possible, outlives the recipient. In the case of prosthesis degeneration a valve-in-valve procedure has nowadays to be an option. The types of biological valves have different designs, tissues and preparations with implications for their durability .
The Sorin Mitroflow was a bovine pericardial bioprosthesis with unique features: (1) externally on the valve skeleton mounted single sheet of pericardium resulting in (2) long leaflets and (3) relatively large effective orifice area as well as (4) absence of anti-calcification treatment (until the introduction of the DLA model) [6, 7]. Surgeons appreciated the easy implantation of the Mitroflow, especially for a small aortic annulus. The Mitroflow valve was introduced in Europe for use in the aortic and mitral positions with the model 11 in 1982 . As with the other bioprostheses, structural valve degeneration (SVD) occurred and was first described in detail by Loisance et al. in 1989 . Subsequently abrasion of the pericardium by the ribbed side of the sewing ring resulting in tears were identified as one reason. This led to the modification of the valve with the model 12A in 1991, where the smooth side of the sewing ring was turned to the pericardium , the use in mitral position of the once Mitroflow labelled valve was abandoned. In 2006 after manufacturing modifications and minor design variations the model LXA followed . The Sorin Mitroflow valve gained wide acceptance and the implantation rate worldwide passed 100,000 in 2011 . The model DLA, introduced from 2011 on, was manufactured with anti-calcification treatment . In 2015 the Sorin Mitroflow was rebranded as LivaNova Crown PRT, which differs from the Mitroflow DLA only by radiopaque and visible markers . Recently data emerged that even the advanced versions of the Sorin Mitroflow (LXA, DLA, Crown PRT) was prone to specific problems. Here we report our experience with this valve.
Case vignette (Patient no. 2)
The 79-year-old female patient had suffered from shortness of breath New York Heart Association (NYHA) grade III for 3 months due to severe aortic valve stenosis. Surgical valve replacement was performed with a Sorin Mitroflow 23-mm Bioprosthesis. Two and a half years later the cusps of the valve were thickened, fibrotic and/or calcified with reduced mobility and elevated pressure gradients (66/37 mm Hg) corresponding to a moderate aortic stenosis. Five years after SAVR the stenosis was severe (maximum velocity 5.0 m/s, effective orifice area 0.5 cm2, mean gradient 70 mm Hg, Doppler velocity index 0.2) and a second aortic valve replacement was necessary in the now 84-year-old woman. An Edwards Perimount Magna 21-mm Bioprosthesis was implanted with excellent follow-up up to today.
We reviewed all records of prospectively collected valve patients of the in- and outpatient clinic of the Kantonsspital Münsterlingen and of a private cardiologic practice (MF). We extracted all patients who had a Sorin Mitroflow Aortic Bioprosthesis implanted. The primary SAVRs were performed between December 2008 and August 2016. The follow-up of clinical and echocardiographic data was completed in April 2021. The protocol of this study was approved by the Ethikkommission Ostschweiz (EKOS Project ID 2020-01340).
Anthropometric data, clinical history, surgery reports with indications and procedures, prosthesis size, indications for rehospitalisation as symptoms of heart failure and all clinical reports were reviewed retrospectively.
All echocardiograms of the patients were reviewed by a single experienced echocardiographer (FW). The examinations were recorded by different operators according to the protocol of our institutions. A few data sets were incomplete, i.e., baseline transthoracic echocardiography (TTE) 3 months after the operation was not available for every single patient. The aortic valve was imaged by TTE and in 17 of the 31 patients also by transoesophageal echocardiography (TOE). Maximum velocities, and maximum and mean Doppler gradients were recorded; the highest values until reintervention or death were reported. The severity of stenoses were calculated by different methods (effective orifice area, dimensionless index, Doppler signal contour, ratio acceleration time / ejection time, planimetry by TOE), patient-prosthesis mismatch was checked and correction for pressure recovery was applied in cases of small aorta ascendens (<3.0 cm). The morphology (thickened, calcified) and the mobility of the valve were described. The insufficiency was classified as transvalvular or paravalvular, small, moderate or severe. In summary, the structural valve degeneration was classified using the standardised definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves .
We used descriptive statistic for tables and figures, standard deviations (SDs) were calculated and significance was computed by Fisher’s exact test.
During a period of 8.5 years (December 2008 to Aufust 2016) we followedup a total of 57 patients after SAVR with a Sorin Mitroflow valve. One of these patients was lost to follow-up, one patient was excluded owing to an associated hypertrophic obstructive cardiomyopathy and another one due to endocarditis 2 months after SAVR. Twenty three patients had normal valves or minor alterations 3 months to 8 years after SAVR. The remaining 31 patients constitute the study population with moderate/severe structural valve degeneration. Their demographic and medical characteristics are summarised in table 1.
Of these 31 patients, 14 were male and 17 were female. The indication for the primary aortic valve replacement was either aortic stenosis or aortic insufficiency. Eighteen patients (58%) received the model Mitroflow LXA and 13 patients (42%) the anticalcification-treated model DLA. The mean age at operation was 76.9 years (range 63–89, SD ± 6.4), 18 patients had isolated SAVR, in 13 patients SAVR was combined with other procedures, namely coronary artery bypass graft (CABG) (7), aortic root replacement or aorta ascendens reduction (5), mitral valve repair (1) and maze procedure (2) (table 1). The mean age of the patients at SAVR did not differ between patients with (76.9 years, range 63–89, SD ± 6.4) and without (76.5 years, range 52–87, SD ± 7.5) moderate/severe SVD (fig. 2). No statistically significant differences were found between SVD and non-SVD patients regarding sex (p = 0.0996), age younger than 70 years (p = 1.0) and prostheses size (19/21 versus >23 mm; p = 0.628). Similarly, the size of the Sorin Mitroflow valve did not to have a significant impact on the SVD severity (p = 1.0) (fig. 3).
|Baseline characteristics||Cohort (n = 54)|
|Non-significant SVD, n||23|
|Male sex, n (%)||16 (70)|
|Average age, years (range)||76.5 (52–87)|
|Significant SVD, n||31|
|Male sex, n (%)||14 (45)|
|Sorin Mitroflow LXA prosthesis (%)||18 (58)|
|Sorin Mitroflow DLA prosthesis (%)||13 (42)|
|Age at SAVR, years (range)||76.9 (63–89)|
|Age at diagnosis of SVD, years (range)||81.9 (69–92)|
|Surgical procedure||n (%)|
|Isolated AVR (maze procedure 2x)||18 (58)|
|AVR and CABG||7 (23)|
|AVR and aortoplasty||5 (16)|
|AVR and MVR||1 (3)|
|Clinical signs of SVD|
|Shortness of breath||3 (10)|
|Heart failure||20 (65)|
|Heart failure hospitalisation||15 (48)|
Moderate or severe structural valve degeneration (SVD) was diagnosed at a mean of 5.3 years (range 2.4–9, SD ± 1.8) after SAVR at an average age of 81.9 years (range 69–92, SD ± 6.0). Four of 11 patients (36%) with the model LXA, 7 of 11 (57%) with the model DLA developed moderate/severe SVD within 5 years after SAVR. Clinical symptoms and signs at diagnosis of SVD were a murmur (18), shortness of breath (13) and congestive heart failure (20) (table 1). Fifteen patients (48%) were hospitalised because of heart failure.
After diagnosis of SVD 16 patients (52%) had a second aortic valve replacement (SAVR 8, TAVI 7, transapical AVR 1) and 15 patients (48%) were treated conservatively: 4 patients (13%) were only followed-up and 11 patients (35%) died without intervention. The reasons not to reintervene were non-severe SVD, serious comorbidities and/or refusal of the patient. The reinterventions in 16 patients were performed at a mean age of 79.5 years (range 69–91, SD ± 5.9), on average 6.9 years (range 5.2–11.9, SD ± 1.9) after the index operation (table 2). The indications for reintervention were severe prosthesis stenosis in five (31%), severe regurgitation in seven (44%) and severe combined bioprosthesis disease in four patients (25%). The four patients still alive without intervention had a mean age of 87 years (range 84–90, SD ± 2.5), on average 8.7 years (range 6.8–9.6, SD ± 1.3) after the primary SAVR (table 2). The 11 patients who died without reintervention passed away at a mean age of 89 years (range 82–95, SD ± 3.7), 7 years on average (range 5.2–9.9, SD ± 1.9) after the index operation. In 7 of these 11 patients, SVD was judged to be the principal cause of death, two patients died because of comorbidities and in two the cause of death is not known.
|Patient age and time intervals in years||Average (range)|
|Time interval in years from index operation to|
|Diagnosis of moderate/severe SVD (n = 31)||5.3 (2.4–9.2)|
|End of follow-up without intervention (n = 4)||8.7 (6.8–9.6)|
|Reintervention (n = 16)||6.9 (5.2–11.9)|
|Death (n = 11)||7.0 (5.2–9.9)|
|Patients without re-intervention (n = 15)||88.5 (84–95)|
|Patients alive (n = 4)||87.0 (84–90)|
|Patients deceased (n = 11)||89.0 (84–95)|
|Patients with re-intervention (n = 16)||79.5 (69–91)|
|SAVR (n = 8)||77.9 (69–84)|
|TAVI (n = 7)||79.7 (76–86)|
|Transapical AVR (n = 1)||91|
The signs of SVD consisted of thickening of the cusps, restricted cusp mobility, calcification or rupture of the cusps of the bioprosthesis (table 3). The changes were categorised according to the standardised definition of SVD for surgical and transcatheter bioprosthetic aortic valves . The classification of SVD severity was based on the morphological appearance of the leaflets and the Doppler measurements, namely AV Vmax, AV mean gradient, effective orifice area, aortic valve area index (AVAi), Doppler velocity index (dimensionless index) and the prolonged acceleration time of the continuous wave Doppler signal >100 ms. If the left ventricular outflow tract diameter was difficult to measure, the outer diameter of the sewing ring was substituted. There were no cases of patient-prosthesis mismatch either calculated by the effective measurements or by the official Sorin Mitroflow EOAi-Chart. The effective orifice area (EOA) calculations were corrected for energy loss index in the cases of small aorta ascendens. Table 3 summarises the type of the index operation, severity of SVD, echo parameters and outcomes. We did not find a SVD-age correlation that means, the older the patient the lesser extent was the SVD (fig. 2).
|Pat. No.||Surgery||Mitroflow, mm, model (LXA or DLA)||Degree of SVD||AV max (m/s)||AVA Index||DVI||Death after first sign of SVD (months)||Implication, re-operation procedure|
|1||AKE, ACBOPx5||25, LXA||Severe||2.74||1.00||0.52||TAVI, valve in valve|
|2||AKE, ACBOPx1||23, LXA||Severe||5.00||0.24||0.20||Redo SAVR Perimount Magna 21 mm|
|3||AKE||21, LXA||Moderate||3.00||0.58||0.32||24||No intervention, death|
|4||AKE||23, LXA||Moderate||2.40||0.73||0||No intervention, death|
|5||AKE, ACBOPx4||23, LXA||Moderate||3.00||0.68||0.32||65||No intervention, death|
|6||AKE||23, LXA||Severe||3.50||0.46||0.40||Redo SAVR Perimount Magna 21 mm|
|7||AKE, ACBOPx2||23, DLA||Severe||4.00||0.62||0.22||0||No intervention, death|
|8||AKE||23, LXA||Moderate||4.20||0.53||0.24||Watchful waiting, 84 years old|
|9||AKE||27, LXA||Severe||0.56||Redo SAVR Perimount Magna 23 mm|
|10||AKE, ACBOPx1||25, DLA||Severe||4.22||0.30||0.20||Redo SAVR Perimount Magna 23 mm|
|11||AKE, MKR||29, DLA||Severe||5.17||0.25||0.10||TAVI, valve in valve|
|12||AKE, MAZE||27, DLA||Moderate||3.05||1.13||0.43||0||No intervention, death|
|13||AKE||23, DLA||Severe||3.80||0.61||0.26||Redo SAVR, Perimount Magna 21 mm|
|14||AKE||27, DLA||Severe||0.26||TAVI, valve in valve|
|15||AKE, MAZE||27, LXA||Severe||2.80||1.14||0.64||Redo SAVR, Sorin Carbomedics 25 mm|
|16||AKE||25, LXA||Severe||4.40||0.45||0.37||TAVI, valve in valve|
|17||AKE||23, DLA||Severe||3.60||0.60||27||No intervention, death|
|18||AKE, ACBOPx2||23, LXA||Severe||4.24||0.56||0.30||12||No intervention, death|
|19||AKE||23, LXA||Moderate||3.60||0.71||0.34||0||No intervention, death|
|20||AKE||23, LXA||Moderate||2.80||0.73||0.35||Wacthful waiting, 87 years old|
|21||AKE, Rohrproth.||25, DLA||Severe||2.78||1.41||0.63||Redo SAVR, Perimount Magna 23mm|
|22||AKE, AoReduk.||25, LXA||Severe||3.16||0.54||0.24||Watchful waiting, 86 years old|
|23||AKE||21, DLA||Severe||5.40||0.28||0.18||TAVI, valve in valve|
|24||AKE||27, LXA||Severe||2.80||TAVI, valve in valve|
|25||AKE||23, DLA||Severe||3.61||0.32||48||No intervention, death|
|26||AKE, Ao Reduk.||25, LXA||Severe||4.04||0.47||0.21||Redo SAVR, Sorin Crown PRT|
|27||AKE||23, DLA||Severe||3.45||0.59||0.24||Watchful waiting, 90 years old|
|28||AKE, Ao Reduk.||25, LXA||Moderate||3.00||0.51||0.34||40||No intervention, death|
|29||AKE, ACBOPx4||25, DLA||Severe||2.80||0.56||TAVI, valve in valve|
|30||AKE||21, LXA||Moderate||2.73||0.59||0.36||27||No intervention, death|
|31||AKE, suprac. Ersatz||23, DLA||Severe||3.00||0.80||0.37||Transapical AVR, valve in valve|
Our series of 31 patients after surgical aortic valve replacement with a bovine Sorin Mitroflow bioprosthesis documents an unusual pattern of early severe SVD even in very old patients (fig. 1, videos A and B). We had never seen clinically significant SVD in patients >75 years at operation before. Our patients had a mean age of 76.9 years, at which the implantation of the Mitroflow should have been the definitive solution of their aortic valve disease. Despite well-established predictors of bioprosthesis longevity, especially old age, significant SVD was diagnosed on average 5.3 years after Mitroflow implantation, and the earliest occurred after 2.4 years. This led to additional suffering for our old patients and increased burden to the healthcare system, particularly rehospitalisations and reinterventions. Forty-eight percent of the patients had heart failure hospitalisations, 52% of the patients underwent a reintervention 6.9 years after the primary procedure and 35% died without reintervention at a mean of 8.1 years after the surgical valve replacement, most of them prematurely due to heart failure caused by SVD. These very old patients were too sick for and/or declined reintervention.
The very early SVD in our old cohort was unexpected and is exceptional in the first decade after SAVR . In general, bioprosthetic heart valves have reoperation rates of 10% and 30% at 10 and 15 years, respectively, in elderly patients . None of our patients had well-established predictors of early bioprosthetic valve degeneration such as younger age (<60 years), severely reduced kidney function / haemodialysis, patient prosthesis mismatch, very small valve size and/or infective endocarditis ([11–14], table 4). Several studies report acceptable , favourable  or good [17–20] or even excellent long-term results of the Mitroflow bioprosthesis [21, 23], preferentially in patients older than 70 years. Only after the clinical series of Alvarez et al. in 2009 , and Saleeb et al. and Sénage et al. in 2014 [25, 26]), along with the pathology study of Butany et al. in 2011 , the appraisal of the Sorin Mitroflow changed markedly two decades after introduction of the Mitroflow 12A. Subsequent nonrandomised comparative single-centre series showed evidence of an inferior durability and/or survival of the Mitroflow valve compared with the Carpentier Edwards (CE) valves Perimount, Perimount Magna [28–31] and Perimount Magna Ease , as well as the Medtronic valve Mosaic . Moreover, in a very large British registry study, the Sorin Mitroflow showed significantly lower survival than all other valves . Similarly, a meta-regression analysis of studies found a significantly higher SVD risk for Sorin pericardial valves (including the Mitroflow valve) than for CE pericardial or porcine valves or Medtronic porcine valves . In Switzerland its limited longevity was hitherto only addressed by a dramatic case report in 2015 .
Why did it take so long until the early SVD even in very old patients was acknowledged? Retrospectively, the discrepancy between the reassuring studies stating acceptable to excellent longevity and the inferior results of more recent studies can be largely explained by the combination of the following factors in the former: (1) restrictive definition of SVD in surgical studies where it was diagnosed only at reoperation [26, 32, 36], (2) the absence of systematically recorded echocardiographic follow-up data [31, 36] and (3) no consideration of the competing risk of death [37, 38], especially in the very old patients. With a high rate of early deaths  and midterm mortality rates of 57.7% to 81.2% in 10 years [17–20, 22] symptomatic severe SVD could either not develop or could not be detected without frequent regular echocardiographic monitoring before death in a considerable portion of patients. Additional factors may have been small single- or oligo-centre studies and lack of direct comparison with other bioprostheses. Thus, it seems likely that SVD occurred much more frequently and was systematically underestimated in the earlier studies. This was impressively underscored by the nationwide echocardiographic study of Issa et al. in Denmark in 2018 . After the substantial SVD risk of the Sorin Mitroflow became apparent, all Danish patients still alive with this valve (644 of an initial 1552) were invited for an echocardiographic follow-up examination; 574 participated, 30% of them were diagnosed with SVD and 11% had severe SVD. The incidence of newly detected severe SVD in patients not reoperated on was as high as the already known incidence of SVD at reoperation, figures that are very similar to our data. Even this comprehensive Danish study probably underestimated the absolute numbers of cases of severe SVD because undetected SVD is likely to have occurred in the patients who declined participation and in the large group of deceased patients.
Historically the diagnosis of SVD was not standardised and often based on severe SVD at reoperation, a long time after significant degeneration had ensued. As Dvir and Bourgouignon et al., on behalf of the Valve in Valve International Data Group (VIVID), emphasised in 2018 in a Circulation White Paper, 20 different definitions of SVD were used in the literature . Following the course of the development of a native aortic stenosis, they standardised the definition of SVD into stages 1–3 for stenosis and insufficiency. In addition to the definition of the VIVID group, the consensus of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the European Association for Cardio-Thoracic Surgery (EACTS) published another definition of SVD in 2017 . Both statements recommend similar haemodynamic and morphological echocardiographic criteria to diagnose moderate or severe SVD. We have used the more detailed definition according to the natural aortic valve disease proposed by the VIVID Group (table 5).
A major mode of SVD in explanted Mitroflow pericardial valves was calcification as presented by Butany et al . The models 11, 12A and the next, third generation model LXA – used in our series in 58% – were not treated with anti-calcification agents to delay SVD like other contemporary bioprostheses. The absence of anti-mineralisation treatment may have been an important reason for rapid degeneration of the bioprostheses in our cohort and in other series [25, 36, 41–42], but this is not completely understood because in 25% of cases the SVD occurs without leaflet mineralisation . Additionally, tears in the para stent regions were diagnosed, which may have been due to mechanical stress and abrasion associated with the special design of this valve . Whether the recent anti-calcification treatment of the Mitroflow model DLA and the LivaNova Crown PRT – which is the same newly labeled valve with radiographic markers – will significantly improve the long-term durability remains uncertain. Initial studies reported discrepant performances and further publications have raised scepticism about the efficacy of the anti-calcification treatment of the Mitroflow DLA / LivaNova Crown PRT [43–45]. Likewise, the high proportion of moderate/severe SVD in our patients (42%) with the new DLA model may indicate that the problem of early SVD is not solved.
Remarkably, there is another bioprothesis – the Trifecta – with an externally mounted single sheet of pericardium, which was introduced in 2010 and had anti-calcification treatment from the outset. This valve showed inferior midterm results due to SVD as well compared with the CE Perimount and Perimount Magna Ease valves, like the Sorin Mitroflow [46–49]. In the study of Lam and coworkers the worse outcomes of the Trifecta and Sorin Mitroflow were similar . These results may indicate that the mechanical stress on the externally mounted pericardium could be a main factor for the development of SVD, more important than the anti-calcification treatment itself.
When severe SVD is diagnosed a reintervention will be contemplated unless the patient is too sick or refuses an invasive procedure. In our patients, the mean age at reintervention was 79.6 years, which is nowadays a typical age for attempting a valve-in-valve TAVI to avoid a second SAVR. However, this was only feasible in about half of our patients with reintervention, mainly because of the risk of coronary ostium obstruction by the cusps – a particular problem of the Sorin Mitroflow valve with its long, externally mounted cusps . In the meantime, sophisticated techniques have been developed to ensure high success rates with valve-in-valve TAVI even in Mitroflow bioprostheses [51–55].
Given the increasing rates of bioprosthesis implantation, especially in patients less than 60 years of age, what can we do to prevent future delays in the recognition of possible problems in new surgical bioprosthetic valves? In our opinion a mandatory SAVR registry analogous to the SWISS TAVI registry should be established. This could ultimately enable even the comparison of hard endpoints, especially overall mortality. It appears to be quite inconsistent, when we follow-up the usually very old TAVI patients regularly every year, while monitoring the much younger SAVR patients who have considerably more life and valve years at risk as well as a higher risk for early SVD is only lenient. In such a SAVR registry every SAVR patient should be followed-up clinically and echocardiographically at yearly intervals, so that the performance of different valves can be compared in a timely fashion. Care must be taken to ensure uniform assessment and reporting by broad education of the standards for SVD diagnosis [39–40].
First, due to non-uniform coding in one of our two institutions, we cannot present the overall number of patients with a Mitroflow bioprothesis seen during the period from 2008 to 2016. Thus, a selection bias is possible. In the other institution (MF Kardiologische Praxis Weinfelden) 21 such patients were monitored and significant SVD was detected in 35% (6/17) of patients with an echocardiographic follow up of >1.5 years; 24% (4/17) had severe SVD and 12% (2/17) had to undergo a reintervention or died because of SVD. During the same study period, an additional 14 patients with different bioprotheses were followed up there, none developed significant SVD. These subset data argue against a major selection bias. Second, several studies identified small valve size as a risk factor for SVD in Mitroflow valves [14, 26, 36, 38] due to patient prosthesis mismatch. This was not evident in our series, which was probably related to the small numbers and absence of the very small 19-mm Mitroflow prosthesis. Third, we did not take into account the possibility of leaflet thrombosis in our cohort of patients. This potential risk factor for early SVD of bioprosthetic valves is rare and appears 1–6 years after SAVR .
The Sorin Mitroflow bioprosthesis was prone to early SVD even in very old patients, as shown in our series. This may be at least in part due to its specific design with an externally mounted pericardial sheet and a former lack of anti-calcification treatment. The frequent SVD led to additional suffering of the patients and added healthcare expense due to reinterventions and hospitalisations. The inferior durability of advanced versions of this bioprosthesis was largely undetected for almost 2 decades mainly because earlier studies diagnosed SVD only at reoperation, lacked regular echocardiographic monitoring and did not consider the competing risk of death despite high mortality rates in this patient group. To avoid a similar delay in the recognition of specific problems with new surgical valves the introduction of mandatory SAVR registries is suggested analogous to the ongoing TAVI registries. These should embrace regular echocardiographic monitoring and uniform definition of SVD as well as broad training of all cardiologists and echocardiographers involved in SVD screening and treatment. Eventually, the results of SAVR-registries would strongly support the surgeons (and the heart teams) in the important responsibility to protect the patient from valve degeneration.
|Severe reduced kidney function with haemodialysis|
|Patient prosthesis mismatch|
|Early valve thrombosis (?)|
|∆p mean >50% of baseline|
|Thickened cusps with or without calcification|
|Reduced mobility of one or more cusps|
No financial support and no other potential conflict of interest relevant to this article was reported.
Fritz Widmer, MD
Medizinische Klinik, Kardiologie
1 . Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep;368(9540):1005–11. http://dx.doi.org/10.1016/S0140-6736(06)69208-8 PubMed
2 Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use—an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg. 2011 Oct;142(4):776–782.e3. http://dx.doi.org/10.1016/j.jtcvs.2011.04.048 PubMed
3 . National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg. 2015 May;149(5):1262–9.e3. http://dx.doi.org/10.1016/j.jtcvs.2015.01.052 PubMed
4 . Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42 776 patients. Eur J Cardiothorac Surg. 2018 Mar;53(3):552–9. http://dx.doi.org/10.1093/ejcts/ezx408 PubMed
5 Durability data for bioprosthetic surgical aortic valve. A systematic review. JAMA Cardiol. 2019 Jan;4(1):71–80. http://dx.doi.org/10.1001/jamacardio.2018.4045 PubMed
6 Clinical and hemodynamic performance of the Sorin Mitroflow pericardial bioprosthesis. December 9th, 2011. www.intechopen.com. DOI: http://dx.doi.org/10.5772/24766
7 . The Mitroflow aortic valve: A past, present, and future illuminated. J Thorac Cardiovasc Surg. 2017 Jan;153(1):40–2. http://dx.doi.org/10.1016/j.jtcvs.2016.10.034 PubMed
8 . Mitroflow pericardial bioprosthesis: clinical performance to ten years. Ann Thorac Surg. 1995 Aug;60(2 Suppl):S305–9. http://dx.doi.org/10.1016/0003-4975(95)00307-7 PubMed
9 . The Mitroflow pericardial valve. First five years of follow-up evaluation. ASAIO Trans. 1989 Jul-Sep;35(3):304–7. http://dx.doi.org/10.1097/00002216-198907000-00041 PubMed
10 Crown PRT Aortic Pericardial Heart Valve with PR Treatment. Minor Design Modifications to Mitroflow DL. Jan 2016 FDA Premarket Approval (PMA), FDA Home, Medical Devices, Database. URL
11 . Aortic bioprosthetic valve durability: incidence, mechanisms, predictors, and management of surgical and transcatheter valve degeneration. J Am Coll Cardiol. 2017 Aug;70(8):1013–28. http://dx.doi.org/10.1016/j.jacc.2017.07.715 PubMed
12 . Noncalcific mechanisms of bioprosthetic structural valve degeneration. J Am Heart Assoc. 2020 ;10(3):e018921. http://dx.doi.org/10.1161/JAHA.120.018921 PubMed
13 . Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009 Feb;119(7):1034–48. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.778886 PubMed
14 The fate of small-size pericardial heart valve prostheses in an older patient population. J Thorac Cardiovasc Surg. 2017 Jan;153(1):31–39.e2. http://dx.doi.org/10.1016/j.jtcvs.2016.08.063 PubMed
15 Predictors of survival and modes of failure after Mitroflow aortic valve replacement in 1,003 adults. Ann Thorac Surg. 2015 Aug;100(2):560–7. http://dx.doi.org/10.1016/j.athoracsur.2015.03.002 PubMed
16 . The Italian study on the Mitroflow postoperative results (ISTHMUS): a 20-year, multicentre evaluation of Mitroflow pericardial bioprosthesis. Eur J Cardiothorac Surg. 2011 Jan;39(1):18–26. http://dx.doi.org/10.1016/j.ejcts.2010.03.069 PubMed
17 . Mitroflow pericardial bioprosthesis in the aortic position. Low incidence of structural valve deterioration in elderly patients during an 11-year follow-up. Scand Cardiovasc J. 2000;34(2):192–6. http://dx.doi.org/10.1080/14017430050142242 PubMed
18 . Mitroflow synergy prostheses for aortic valve replacement: 19 years experience with 1,516 patients. Ann Thorac Surg. 2005 Nov;80(5):1699–705. http://dx.doi.org/10.1016/j.athoracsur.2005.04.053 PubMed
19 . Long-term outcome of the MitroFlow pericardial bioprosthesis in the elderly after aortic valve replacement. J Heart Valve Dis. 2006 Mar;15(2):197–202. PubMed
20 Long-term outcomes and durability of the Mitroflow aortic bioprosthesis. J Card Surg. 2016 May;31(5):264–73. http://dx.doi.org/10.1111/jocs.12726 PubMed
21 CarboMedics Mitroflow pericardial aortic bioprosthesis - performance in patients aged 60 years and older after 15 years. Thorac Cardiovasc Surg. 2008 Jun;56(4):195–9. http://dx.doi.org/10.1055/s-2008-1038385 PubMed
22 Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg. 2008 Sep;136(3):688–96. http://dx.doi.org/10.1016/j.jtcvs.2008.05.022 PubMed
23 . Mitroflow pericardial aortic bioprosthesis in patients younger than 60 years. J Thorac Cardiovasc Surg. 2010 Nov;140(5):e83–4. http://dx.doi.org/10.1016/j.jtcvs.2010.07.015 PubMed
24 Early calcification of the aortic Mitroflow pericardial bioprosthesis in the elderly. Interact Cardiovasc Thorac Surg. 2009 Nov;9(5):842–6. http://dx.doi.org/10.1510/icvts.2009.204958 PubMed
25 Accelerated degeneration of a bovine pericardial bioprosthetic aortic valve in children and young adults. Circulation. 2014 Jul;130(1):51–60. http://dx.doi.org/10.1161/CIRCULATIONAHA.114.009835 PubMed
26 Early structural valve deterioration of Mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients. Circulation. 2014 Dec;130(23):2012–20. http://dx.doi.org/10.1161/CIRCULATIONAHA.114.010400 PubMed
27 . Modes of failure in explanted mitroflow pericardial valves. Ann Thorac Surg. 2011 Nov;92(5):1621–7. http://dx.doi.org/10.1016/j.athoracsur.2011.06.092 PubMed
28 Durability after aortic valve replacement with the Mitroflow versus the Perimount pericardial bioprosthesis: a single-centre experience in 2393 patients. Eur J Cardiothorac Surg. 2016 Jun;49(6):1705–10. http://dx.doi.org/10.1093/ejcts/ezv432 PubMed
29 Comparison of survival after aortic valve replacement with Mitroflow or Perimount Prostheses. Semin Thorac Cardiovasc Surg. 2019;31(3):350–8. http://dx.doi.org/10.1053/j.semtcvs.2018.11.016 PubMed
30 Mitroflow and Perimount Magna 10 years outcomes a direct propensity match analysis to assess reintervention rates and long follow-up mortality. J Card Surg. 2019 Nov;34(11):1279–87. http://dx.doi.org/10.1111/jocs.14250 PubMed
31 Long-term outcomes following surgical aortic bioprosthesis implantation. J Am Coll Cardiol. 2018 Apr;71(13):1401–12. http://dx.doi.org/10.1016/j.jacc.2018.01.059 PubMed
32 Early structural valve deterioration and reoperation associated with the mitroflow aortic valve. J Card Surg. 2018 Dec;33(12):778–86. http://dx.doi.org/10.1111/jocs.13953 PubMed
33 National Registry data and record linkage to inform postmarket surveillance of prosthetic aortic valve models over 15 years. JAMA Intern Med. 2017 Jan;177(1):79–86. http://dx.doi.org/10.1001/jamainternmed.2016.6936 PubMed
34 . Bioprosthetic aortic valve durability: A meta-regression of published studies. Ann Thorac Surg. 2017 Sep;104(3):1080–7. http://dx.doi.org/10.1016/j.athoracsur.2017.02.011 PubMed
35 . Sudden cardiac arrest during emergency caesarean delivery in a 31-year-old woman, due to accelerated structural valve degeneration of an aortic valve bioprosthesis. BMJ Case Rep. 2015 Nov;2015 nov13 2:bcr2015212575. http://dx.doi.org/10.1136/bcr-2015-212575 PubMed
36 Real structural valve deterioriation of the Mitroflow aortic prosthesis: competing risk analysis. Rev Esp Cardiol (Engl Ed). 2017 Dec;70(12):1074–81. http://dx.doi.org/10.1016/j.rec.2017.02.041 PubMed
37 . Structural valve deterioration of bioprosthetic aortic valves: an underestimated complication. J Thorac Cardiovasc Surg. 2019 Apr;157(4):1383–1390.e5. http://dx.doi.org/10.1016/j.jtcvs.2018.08.086 PubMed
38 Structural valve deterioration in the Mitroflow biological heart valve prosthesis. Eur J Cardiothorac Surg. 2018 Jan;53(1):136–42. http://dx.doi.org/10.1093/ejcts/ezx321 PubMed
39 . Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Leon MB et al. On behalf of VIVID Investigators. Standardized definition of structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. White Paper. Circulation 2018 Jan;137(4):388-399.
40 Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2017 Sep;52(3):408–17. http://dx.doi.org/10.1093/ejcts/ezx244 PubMed
41 . Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic heart valves. J Thorac Cardiovasc Surg. 2014 Apr;147(4):1219–24. http://dx.doi.org/10.1016/j.jtcvs.2013.03.025 PubMed
42 Long-term results of the Mitroflow aortic pericardial bioprosthesis in over 800 patients: limited durability and mechanisms of dysfunction. Eur J Cardiothorac Surg. 2017 Aug;52(2):264–71. http://dx.doi.org/10.1093/ejcts/ezx161 PubMed
43 Early structural degeneration of Mitroflow aortic valve: another issue in addition to the mismatch? J Thorac Dis. 2018 Apr;10(4):E270–4. http://dx.doi.org/10.21037/jtd.2018.03.137 PubMed
44 Effect of bioprostheses anti-calcification treatment: comparative follow-up between Mitroflow LX and Magna pericardial xenografts using a propensity score-weighted analysis. Interact Cardiovasc Thorac Surg. 2017 Mar;24(3):335–41. PubMed
45 An unexpected risk factor for early structural deterioration of biological aortic valve prostheses. Ann Thorac Surg. 2018 Feb;105(2):521–7. http://dx.doi.org/10.1016/j.athoracsur.2017.07.014 PubMed
46 . Reintervention after aortic valve replacement: comparison of 3 aortic bioprostheses. Ann Thorac Surg. 2020 Aug;110(2):615–21. http://dx.doi.org/10.1016/j.athoracsur.2019.10.060 PubMed
47 Trifecta versus Perimount Magna Ease aortic valve prostheses. Ann Thorac Surg. 2020 Sep;110(3):879–88. http://dx.doi.org/10.1016/j.athoracsur.2019.12.071 PubMed
48 Durability and performance of 2298 Trifecta aortic valve prostheses: A propensity-matched analysis. Ann Thorac Surg. 2021 Apr;111(4):1198–205. http://dx.doi.org/10.1016/j.athoracsur.2020.07.040 PubMed
49 . Different rates of bioprosthetic aortic valve failure with Perimount and Trifecta Bioprostheses. Front Cardiovasc Med. 2022 Jan;8:822893. http://dx.doi.org/10.3389/fcvm.2021.822893 PubMed
50 . Coronary obstruction following transcatheter aortic valve-in-valve implantation for failed surgical bioprostheses. Catheter Cardiovasc Interv. 2011 Feb;77(3):439–44. http://dx.doi.org/10.1002/ccd.22861 PubMed
51 Efficacy and safety of transcatheter valve-in-valve replacement for Mitroflow bioprosthetic valve dysfunction. J Card Surg. 2018 Jul;33(7):356–62. http://dx.doi.org/10.1111/jocs.13720 PubMed
52 . D. Dvir D, Wood DA, Webb JG. Aortic valve-in-valve in externally mounted bioprosthesis. A safe treatment option for bioprosthetic structural valve dysfunction. Innovations (Phila). 2018 May/Jun;13(3):171–6. http://dx.doi.org/10.1097/imi.0000000000000500 PubMed
53 Chimney stenting for coronary occlusion during TAVR. Insights from the Chimney registry. JACC Cardiovasc Interv. 2020 Mar;13(6):751–61. http://dx.doi.org/10.1016/j.jcin.2020.01.227 PubMed
54 High-pressure balloon fracturing of small dysfunctional Mitroflow bioprostheses facilitates transcatheter aortic valve-in-valve implantation. EuroIntervention. 2017 Oct;13(9):e1020–5. http://dx.doi.org/10.4244/EIJ-D-17-00244 PubMed
55 . Bioprosthetic valve leaflet thrombosis. How the past may inform us about the future. J Am Coll Cardiol. 2020 Mar;75(8):867–9. http://dx.doi.org/10.1016/j.jacc.2019.12.038 PubMed
Published under the copyright license
“Attribution – Non-Commercial – NoDerivatives 4.0”.
No commercial reuse without permission.